← Back to Search

Carbonic Anhydrase Inhibitor/Alpha-2 Adrenergic Agonist

Brinzolamide/brimonidine ophthalmic suspension for Ocular Hypertension

Phase 3
Waitlist Available
Research Sponsored by Perrigo Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes
Adequate wash-out period prior to baseline of any ocular hypotensive medication.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

Study Summary

This study is evaluating whether a generic version of a drug is as effective as the branded version.

Eligible Conditions
  • Ocular Hypertension
  • Open-Angle Glaucoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean change in intra-ocular pressure

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Perrigo activeExperimental Treatment1 Intervention
Group II: Reference activeActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Brinzolamide/brimonidine ophthalmic suspension
2021
Completed Phase 3
~450

Find a Location

Who is running the clinical trial?

Perrigo CompanyLead Sponsor
43 Previous Clinical Trials
20,909 Total Patients Enrolled
1 Trials studying Ocular Hypertension
495 Patients Enrolled for Ocular Hypertension
Padagis LLCLead Sponsor
36 Previous Clinical Trials
20,402 Total Patients Enrolled
1 Trials studying Ocular Hypertension
495 Patients Enrolled for Ocular Hypertension

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~117 spots leftby Mar 2025